<SEC-DOCUMENT>0001193125-13-300803.txt : 20130725
<SEC-HEADER>0001193125-13-300803.hdr.sgml : 20130725
<ACCEPTANCE-DATETIME>20130724175659
ACCESSION NUMBER:		0001193125-13-300803
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20130725
DATE AS OF CHANGE:		20130724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		13984479

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d573232d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospects Supplement No. </B><B>3</B><B></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(to Prospectus dated May 30, 2013)</B><B> </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed pursuant to Rule 424 (b)(4)</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No. 333-187508 </B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>125,000 Shares of Series A Convertible Preferred Stock </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g573232g08h16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement supplements the prospectus dated May 30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain Prospectus Supplement No. 1 dated July 17, 2013 (&#147;Supplement No.
1&#148;), and by that certain Prospectus Supplement No. 2 dated<BR> July 19, 2013 (&#147;Supplement No. 2&#148;), which forms a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being
filed to update and supplement the information in the Prospectus, Supplement No. 1 and Supplement No. 2 with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;)
on July 24, 2013 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Prospectus, Supplement No. 1, Supplement No. 2 and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible Preferred Stock (&#147;Preferred Stock&#148;)
which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement should be read in conjunction with the Prospectus, Supplement No. 1 and Supplement No. 2. This prospectus
supplement updates and supplements the information in the Prospectus, Supplement No. 1 and Supplement No. 2. If there is any inconsistency between the information in the Prospectus, Supplement No. 1, Supplement No. 2 and this prospectus supplement,
you should rely on the information in this prospectus supplement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is traded on the Nasdaq Global Market
under the trading symbol &#147;ABIO.&#148; On July 24, 2013, the last reported sale price of our common stock was $1.44 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page
</B><B>5</B><B> of the Prospectus and beginning on page </B><B>23</B><B> of our quarterly report on Form 10-Q for the quarterly period ended </B><B>March 31</B><B>, </B><B>2013 </B><B>before you decide whether to invest in shares of our common
stock.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</B> </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>The date of this prospectus supplement is July 24, 2013 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): July&nbsp;24, 2013 (July 22, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;22, 2013, ARCA biopharma, Inc.
(&#147;ARCA&#148;) announced that it has expanded the clinical trial leadership team with three new hires in clinical development and quality assurance. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated
herein by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, on July&nbsp;24, 2013, ARCA announced the Steering Committee for GENETIC-AF, ARCA&#146;s Phase 2B/3 trial
evaluating Gencaro as a potential treatment for atrial fibrillation. The Steering Committee is comprised of experts in the field of cardiology and electrophysiology, particularly in clinical development. The press release is furnished as Exhibit
99.2 hereto, the contents of which are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Additions to GENETIC-AF Leadership Team; Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as Potential
Treatment for Atrial Fibrillation&#148; dated July 22, 2013.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Steering Committee for GENETIC-AF Trial; Cardiology and Electrophysiology Experts to Provide Scientific Oversight and Guidance
for Phase 2B/3 Clinical Trial of Gencaro as a Potential Treatment for Atrial Fibrillation&#148; dated July 24, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: July&nbsp;24, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Additions to GENETIC-AF Leadership Team; Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as Potential
Treatment for Atrial Fibrillation&#148; dated July 22, 2013.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA biopharma Announces Steering Committee for GENETIC-AF Trial; Cardiology and Electrophysiology Experts to Provide Scientific Oversight and Guidance
for Phase 2B/3 Clinical Trial of Gencaro as a Potential Treatment for Atrial Fibrillation&#148; dated July 24, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g573228ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma Announces Additions to GENETIC-AF Leadership Team </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as Potential Treatment for Atrial&nbsp;Fibrillation
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, Colorado, July&nbsp;22, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced that it has expanded the Company&#146;s clinical trial leadership team with three new hires in clinical development and quality assurance: vice president &#150; clinical
development, senior director quality, and senior clinical program manager. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These new hires will join existing ARCA employees in overseeing
the execution of GENETIC-AF, the Company&#146;s Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased to have these industry professionals, who collectively have over 45 years of clinical development and QA experience, join ARCA
as key members of our team,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and CEO. &#147;Their understanding of the drug development process and clinical trial execution will be a tremendous asset as ARCA continues the development of
Gencaro as a potential treatment for atrial fibrillation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Dufton, PhD, Vice President, Clinical Development, was previously
Director of Clinical Research at Gilead Sciences. Prior to Gilead, Dr.&nbsp;Dufton was Associate Director of Clinical Development at Myogen, Inc., where he was a member of the development team responsible for the clinical program that led to the
approval of Letairis&reg; (ambrisentan) for the treatment of pulmonary arterial hypertension (PAH). Letairis is now approved in the U.S. and Europe for the treatment of PAH. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Sharon Perry, Senior Director Quality, was previously Director of Quality Assurance (QA) at Accera Pharma. Ms.&nbsp;Perry also brings additional relevant QA experience from her prior work at Gilead
Sciences, PR Pharmaceuticals and Pfizer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Merriweather, Senior Clinical Program Manager was previously Clinical Program Manager at
Gilead Sciences. Ms.&nbsp;Merriweather also brings additional relevant clinical development experience from her work with Myogen, Inc. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted
atrial fibrillation prevention treatment. ARCA has partnered with Medtronic, Inc. for the Phase 2B portion of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press
release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding execution of the
upcoming GENETIC-AF trial, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the
potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to
meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including
without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations Advisory Solutions </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163, <U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.2 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g573228ex.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA BIOPHARMA ANNOUNCES STEERING COMMITTEE FOR </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENETIC-AF TRIAL </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cardiology
and Electrophysiology Experts to Provide Scientific Oversight and Guidance </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>for Phase 2B/3 Clinical Trial of Gencaro as a
Potential Treatment for Atrial Fibrillation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, July&nbsp;24, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a
biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the Steering Committee for GENETIC-AF, the Company&#146;s Phase 2B/3 trial evaluating GencaroTM (bucindolol hydrochloride) as a
potential treatment for atrial fibrillation. The Steering Committee is comprised of experts in the field of cardiology and electrophysiology, particularly in clinical development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stuart Connolly, MD, Director of the Division of Cardiology at McMaster University in Hamilton, Ontario, has been appointed Chairman of the Steering Committee. William T. Abraham, MD, Director of the
Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, has been appointed co-Chair of the Steering Committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The Steering Committee of GENETIC-AF provides a balance of atrial fibrillation and heart failure clinical trials expertise, with each member being
an expert in one or the other or both,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief Executive Officer of ARCA. &#147;We are delighted to have Dr.&nbsp;Connolly chair the Steering Committee. He brings a wealth of experience over a
distinguished career in the field of electrophysiology, particularly in clinical trials in atrial fibrillation, which makes him a natural fit to help guide the development of Gencaro. Dr.&nbsp;Abraham is also an expert in heart failure clinical
investigation and brings a background of leadership in both drug and device trials in chronic heart failure populations. Thus, GENETIC-AF will have the benefit of trial leadership that is at the forefront of both atrial fibrillation and heart
failure outcome trials.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;I am honored to participate in the GENETIC-AF trial, an innovative approach to evaluating the potential
efficacy of Gencaro as a treatment for atrial fibrillation,&#148; said Dr.&nbsp;Connolly. &#147;Atrial fibrillation is a growing problem where current medical therapy does not provide adequate treatment, particularly in heart failure populations. I
look forward to working with the teams at ARCA and Medtronic to advance a potential new treatment for patients at high risk for developing, or living with, atrial fibrillation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Abraham said, &#147;I am pleased to be closely involved with the GENETIC-AF trial, which explores new territory on two important fronts: prospective identification of a genetic subpopulation
potentially more responsive to a cardiovascular drug, and demonstration that a drug, in this case Gencaro, may be safe and effective in preventing atrial fibrillation in the unmet need population of heart failure with reduced left ventricular
ejection fraction.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Steering Committee members are: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inder Anand, MD, of the University of Minnesota and Director of the Heart Failure Program at the Minneapolis VA Medical Center;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David E. Haines, MD, Director of the Heart Rhythm Center of William Beaumont Hospital; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jonathan P. Piccini, MD, Director, Cardiac Electrophysiology Clinical Trials Program, Duke University Medical Center; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">William H. Sauer MD, Director of the Electrophysiology Program at the University of Colorado Denver; and, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dirk J. van Veldhuisen, MD, Chairman of Cardiology at the University Medical Center Groningen, the Netherlands. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Steering Committee will provide scientific oversight for the GENETIC-AF trial as well as communicate its recommendations regarding trial conduct with
the trial&#146;s Data Safety Monitoring Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENETIC-AF Clinical Trial </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to metoprolol CR/XL for prevention of AF in patients with heart failure and reduced left
ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the
Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated
additional 420 patients. The Company anticipates that patient enrollment in GENETIC-AF will begin in the first quarter of 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA
biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead
product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes
predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the Phase 2B portion of the
GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements regarding, potential timing for patient enrollment in the GENETIC- AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic variations to predict individual patient response
to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in
the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business
objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and
the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the
Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations Advisory Solutions </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163, <U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g573228ex.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g573228ex.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`5`#9`P$1``(1`0,1`?_$`+L```$$`@,!`0``````
M```````!!PD*!@@"`P4$"P$``04``P$```````````````$"`P0%!@<("1``
M``8!`P($!`,%!@,)`````0(#!`4&!P`1""$2,4$3"5$B%!5A<1:!T3(C%_"1
MH4(S"K'!0_%2-$4F-G88*1$``0,"!`,$!P,'#`,``````0`"`Q$$(3$2!4$3
M!E%A,@?P<8&1H=$BP10(L4)2(S,T%O%RDK/3)%24U!4E5407&/_:``P#`0`"
M$0,1`#\`OT2<I'PS%U)RKMO'QS%`[EX^>+I-FK5NF43*++KK&(FFF0`ZB(AJ
MCN.Y6&T64NY;G*R"P@87R2/-&M:.)/R3XXIIY&PV['23.-`UN)]RTJL_N!8.
M@9%:/BVUNMQ6ZADU)""C&*<:<2].YNO+2<:HY3,/@8I-A\?#KKRIU)^,_P`J
M=ANS;VL>X;C;@82VS8#&<2"!S)HW<.+0NSMK\I>H]RMQ<.DMH"[)LA?J]NEC
M@/>O!3]Q3%BH[$HN2?S%G6@#\^MD\!UQC_[P\L0X-.U;Z*BM=%K_`*I:DODG
MU'$-7WJR-1P,O]DN]3W"\8I`F)Z'DD`4*4Y1!G6A`2&#<IM_U)X#I)/QX^6<
M;=9VC?R*_H6O^J3(_)?J!XK][L10\72_V:^4WN,XF3,`*TK)"8"(?,9C7-MA
M'J(;6/<=M./X[_+(-:YVU;Z`X_H6N'>?[UDI!Y)=1$$MN[$D<`Z6O]4MC\2\
MD,59G]5M3YM0DTW)ZKBN3*`1DXDB'BN1HHJHF[0*/B=`ZA2^>VN_O+KST\OO
M,\\CINZ_Y+37D2:6RY5(`#G-)''%<"W[H[>^G7?W^.L'Z;*EGJJ0*'UA/J!@
M'_#S`?$`'R'\==N-F8[^>,",*M-*T/>N+D42[Z=K'>DHC?1K'>BBX&5(00`Y
MBEW$I0[C%*`F,/:4H=PAN8QN@!YCHUA+1<@,`_L\0^&C6$42[Z-8[TE$;]=M
MAT:P<@4(W_`?[OWZ75W%"03;?Y3?L#?1J[BD)IWI0'?R$/STH-0@$G@4ND+@
M,"E2;Z36.]%$;_@/AO\`VZZ-8[T+YE'K1$W:NY00.(`/8LNDF?8?`>TYP'1S
M&#,@'O0-1X%=J:R:I>](Y52#X&3.4Y1Z>1BB)=&MI\./J2T/'!=F_P">C6.]
M%$;Z-8[TE$";;X^&^G!P(U<$E<:+K*LF<3%*8IA+V]P`8HB7N`!*!@`1[1$H
M[AOXAJ-LK7=J?I(%5V;[Z=K":,4;Z4/!-$)=.0HI_<3R9,)256Q1&N56T6YB
M2VNPI)'%+[F8[YPRB&2Y@_U&R!F:RHI[[&/VB._:&OG%^.7S$W:SN;'H';))
M(8>0R[EH:,F:^22/E/H:T_5UI3BN_O)KI^U>V3J2<-=*R8Q-!X`-:XGVZE'S
M6*6\FRJ*-TCKF1(*SAL4HF6%OXJ.4R%W,H1,/X]@$2AUVVZA\_+#8+O>I73[
M?$QMNY]2QA):TT%0.-/FN\-PO8H)"YX#&'$$>$=RV#@,3#*5I>60;BHO!.4$
MI!("B(C&/P-]&]+\2HNB"D<>H!ZA=]M=J[=Y>LW3IV;<6M(;:3`2N(/TMH*N
MH`3I;6KC3B*+BL_4(MMR9;S/#()6?2\^&M3Q6=R^#G3IW2XQDT`'$_7(USN<
MNQ$O56>%76./4"I-T$N\P^10WUS2_P#*H2WVT6=E$7'<+%LC!0XM,DC>8<,&
MNTU![%@,ZKC9'<3/D#FQW!C^GC0--17@:IC+5CL[B2?HQ#<QV+0R_I*FW*1%
MBS$$?K'2AOE0(J4H'$3;;F-L&XB`#U-O_2+K'=+INW:9I;*4P2G'E->T!Q:3
M2I(#@304Q7,K#=Q;L9+*:R2-!`&-`>U,_'2LW0K+&V&OOG#&5@7Z;^,D&_\`
M*.55L;?L-TW,@L7<IR"'S%$0$.NN.;)NU[TUOL6][7-]RW&RD;*'P./U.K0M
M=6F&'Q6U=6D6_P"UR;5N;&&WEJYN&()%,?<K'6-;4%YH52N($!+]2P$9+F2#
M^%)5VT2.NF7Q'L*OW`'X:^[O0&_2]4=%;9U%<`"ZO+-DCZ<74H3AVT7B'>+(
M[=NUS85JV&9S1Z@5F^N7+-1I:85X(56_W^N;=EH=\P3Q[Q38GT38:)-0>?;V
MYB7BS91*6C7AOZ:0#\[95(QD3"W=OUD#")%2'0$0$-4;B8B01M[*J]!;:XS*
M2*5HK$?&[-$'R(P/BG-M=42/&9(I4)9!22,!@8R3IJ1.;BS=1V4BII)PW,'C
MNGJU&'::N()*J/%'4">W3TQ:V\CN-$!R2AH*)F\CYHQHM6W+YY%S6%\E3&.I
M87,@BD@I]U-'$793C=`K<ID4G2*A$SB82["8=12,>XU:>">UP:,53.YP9.YJ
M\0>6=XXSU[FSR(M,%#O:@:M3TOD&<1DE8BZQD9)1J$N#=P"9GT:,B**ZB($(
MMZ?<4I=]@J2F2*3EUQ6C%$SDB4C`JRE5O:K07J\0M=^;O.RR7=6):*RMEC\]
MOH-D:65;$477C(-.(=(M69%S?RTE5%C=@`!C".XZFY4AXC)53<"OT@443')K
MDQSY]H#D14:S-9VL/*GC]>(\]@K++,*3=].24+'OR,[!73V1$@RL-:X8RQ#)
M.45CM5R*IG.@`")`=JDB^DD$*Q"V*ZC+2VDM<U9WX_YJJ'(O#6/,W4-=5:J9
M(K;*QQ:;G8'C`7`&2?1+X"[%*]B)%%9LKMT]1(1#H(:E8[4*]ZSWL,;RQV86
M,<H>4&)>(F(Y[,>8IP8JNQ($:1L<T!)>>M5@=%4^VUJM1ZBJ0OY=^9,1`-RI
MI)E,HH8J9#&!7.#!J=DG11/FD$;,^_)0%85SC[B?O`W:QOZ#?)#A?PXK4PK$
M25@H:8+WRQJ$`BGZ=86U8J+V:LHM5"&>G:G9QL?W]IBK'$I30->ZX!=']+!@
M:^F*F?%';G3)C)W9>GL4F]<]G[AC'QP)72'RKEZP*)E^ON63,VY/E;$_7[0]
M1P8T39(6-:"<^X@5%N0I=]@T]L##^TJ2F.N93E2BTJY9>S79:O4YN_<",[9T
MQO>(1LM*H8A?9;N4C5[25H4ZYH^MR[N6^ZP4T8A.UL1RJZ:JG$""*>X&TQ\!
M;C"<*9%217#2=,PQ[>Q;A>S+EF^99X.5=YE*PVFS9&I>0<DX^M\E='[R2M)9
M*`L:RR+*8=2*BCXSF.CY%%$05'N+Z?;X`&GP$F,US#ODB\C$<H`I0M!^)4K.
MIE46*WBY0&/*;:KY:WR496:979BSS\@L<I$VD3",%Y%\L)CB4!$K=N;M#?<Q
MM@#J.G!P:PU2M%7AHS*JK>TA[B%HRC[BN>8W)$R]3@N6KN5GJ;#R+U<[*N6&
MFBX<TZ$C&ZYA2:$<48%&O8F``JNB41W$=5(IFEQ;C4E:5S:EL8<PC2T*VD'G
MJRLL"BY!IS/$E2ZF2*&;GR@1QG^O$5(91/\`IU"[E`PD_P#/['OL8`-U_9KY
M.?CAE@/G!903GZ#L<&'']XNEZ@\GFG^#9G@C]^D_JXEYN(:0VDG+%Q`6)M%S
M2!DE6;.6'[>J98!#8&DD4%F2P^78IZ7=OML.XZZ_\L.E;*_N/ONQWD$6X0Z-
M5O,[3S&N-`6BA!J:C&F2TNI-PD9:2?>X)Y=N8*ET8!H[L-7#U^U;@R\[6L:/
M$62M<0&^6F%69SE4;.4/T]](NL!2S;@[<ROTA'JJ8F212'<QMQ#M`-]>NM[W
M+8?*^Z#)]O#NI+VR;!/:G0;62WE)US-(<7<TTH`6@$-S`75-K#N75,+(I)/^
M)BDU-?\`G@?HG"E0,#C[2G,@CR$G&IR,C7H]NFE`*UYN^B_6%Y%Q2R9B"5N1
MV=1)11,IQZCL8WAOKENR[Q>[QM<^X;KM\,.WMLV6C7PBLL%MJ<(^54`<P:B7
M8@#@2L>_M8+6<VEG*[29M0#CFX`8FG#`)F<HXU1+#)LX4T/7:7V(.W4Y+2"9
M7EE=BGZA%5$FQ7#]T5L8P@DV*3M(;<P]>NNMO,ORZCL]K%KL[]ML>F8HAKN[
MF41NN)35SGO`#G.DTEK<`6X`5K5<BZ:W^X=?\J_9/+=L.EH8`6M;[2.-:DYJ
M-')$)$LEUTH]9R][`,472J'T*0F`=Q%-L855P*;;_J"4W7P#7SZZRL-ILQ<L
MVU_-HQH,C*%CCJ.+#6I'94`]R[^V.YN99&NN1I!K0=U,%-]QGW#`6*`'KM3H
MP/[BG#_EK[7>1P`\H>GP,O\`;F?:O(765/XIOZ9?>7?E3Y:[47&5B]WN=>QW
M3K5>[8_2BZS3:],6B?D5SE(DRAX)@O)2#@PG,4/D;-S;!_F-L`=1#2N>UD9+
MLDYC2]X8W,JK99.*%CYF>W%R]YLVV"45S9G[)#_DIC-NJAZ\E"8BQ"9]`TVG
M,%#E,Z18OZ(22."1-@6$4#["(%U6='J89,-9Q"NAYCE$/YHP3R_[=#DJ%JQ+
MD_C%-R`JRF,YE/(=(;K*[J'IER5]&<:MNX0,+>(LQ/5[`W[?K]16TA:#&_%U
M:CX(O6@N:]N#=-%96U=5!<1\_P`@_P">EX)'>%42?>J#_P#4RZ;=-V>!Q^'4
M:_`;CK/N_P!X'J^U;40K9-'K5ZF,$`C6(^0,6@_L!LD/AJ\W+V#\BQR*&BJ;
M_P"Y#N4)9<D\7L2P(_>KW#PURG7\'&D%]+-T+>_@8JML!9-05<_6S;F)6,@C
MV^HH!"B`"!@U6N'@2!E#73]I6A9$1@RN\-:*=;VO<&77CIP<P=C+(C=5A=VD
M))6.P0JVP+0#VWS,A9$X%?J8".HMO(II+%_R+`<OEJ:/Z8\>WY*G.\.D+AD5
M5S]ZOD)<.3W.HO'FM/UEJEAV=A<35"%*J;Z)QDNSKQC>U3RZ)1%-5\$E((L"
MG'YDT6G:&W<?>I*]TDXT'Z0*?%:5HP0Q<Y_'L[%<<XW8*I_&O!N-<(4EBW:P
M>/JQ'0PK))$(I*S!4BKST\\$``RK^<F55W2IS;B)E-M]@#5UK0P:1P_*LI[S
M(\N/:GQTY-2"&_\`PTC@2*!":C&&$\<X=>9&>X^@OL"F5<@2F3[FBD\=+LWU
MSFVC%I*RC1HNH=",*^)'IF420*1(5.X^W<81TR-FAI'::IQ<YWBQHG8U(FJ(
M'W7;G+W]E@/@70GZJ-UYC9'C(6X'9'/]5!X,I[UM.9#F'()?.@S?)(D;=^X`
M<A5B_'4<CQ^R_.<IX@`#(>"@.]W'#;G@=SYQ-GG#L46MUB98T7(=+1C4P;L(
MVT8N&+@;'#)^D4J1?N3"-:K+%V`3`]/\=5G1F.2M:@Y+0MG.G@<P^*JN48@R
M77\RXMQ_E>J.$W5=R)48&W12B1_4`C>;C6[TS4YO)=DLJ9%0/\ITQ#Q#5P.#
MQJ"R7-+'%IS!3D!I[/$D2ZF2*'CG2LDCR`@C*HIKA_3J#'M5.J4H%^_64#=4
ME$S!OKY2_C6N.3YS6(=$R1G^QV^>?[Q=?!>E_*0O_@Z9K?\`&O\`ZN)9#A%P
MSEE$$&6-XZ:%/TA6=*2$PBU;!OT,Y<J//H4"AX_-J'REIN-Q#%8]-0WT[Y6!
M]SS.6^)C2"014#0*U!KF3@J_6#=%K(7W<K)',H(&`'5B?J(-,\NW!>9G-T]I
M^;BS+T$"P5@A(3[&X9N/K8Q$8IF1C(0[=Z`]AUXYR3J4?F[3@;;8=5_/N6[Z
M7\V#OV\/$/3,EM$Z)^MTD0(+F\G7IIS`1736E"#7%7.@XV;ET[)80,Y=Y#J+
MM8#7.!R(`KB<LADGGA<]-6U>%D#I,`%+M[0,`[]Q?EW\!$=_`/$1\-<[VCSL
M$?3XL]<8VR\8Z.-X(<'2Z1HCTM+GAQ-#X:8C&JP;OHR4WC+J6-S7#ZSJRI4C
MWIP)I!VOCR$=/J;'6B128NG#ILO).D9F(1>N5WB")XEFJF[``;+%,.WS%WV$
M-@UV1O!EE\MMMFW39K?>=[^[4FB==31RPOU.(U0-T@T86NU'$UID`N*69@DW
MV1C;A\`,F%`-)[]6(KA\%&9E24C7"KH$*^RC#D$X&33<R1S%,4-@(<KET<Y1
M*)=A`=?/KS#W2SOY+N&.-L4L,;6&-NO3$0XGEUD)<2*\,,5Z%Z986Z?UO-H<
M_8,%,GQJ'?`N*1``+O3XT>T-]@W*?H&^XZ^QWD=7_P!1=/U_Z]GY2O)O6!KU
M1?$?XE_Y4^&NU%QM0?\`O99=MCS%F,^%V(HR8M&6>6]M1@W-9K"K9.Q.<7U=
M=*6MB+,[Q5NU:'G5T$VQ%5U$T023<"<P%*.JUR_`0@'6['V?RJY9LH_GFFAJ
M="G<GN0%%QY6\70/M5<BT*75:C&4B,B#7_"ID`KL5$HPJ+-1(+,4B@*L$0!3
MI\XF'?QU*7D,#2Q^7`)',:^0R<QHQXJL;QFO5G]O+W1*^XNE(M&'ZX\O;FLV
MBB6UQ&NIB`Q+EISWPA)1U#N'$/(!!-G[)R59!0R0BW'80$!VH,=HFQ!JKCXC
M<-TQD&@5]]-0BI"JIF*=-0H'34*(&(H0P`)#D,41`Q#E'<!#Q#6D"#EDLDBF
M!S2CY_E^_3N":[PJB'[V9%5?=#OJ2"XMEU8K!R2#D"%4%LNI68,B+D$S"!5!
M05,!^T>AMMAU0N_WD>K[5MPFEFT^M3(<^R^[3Q4P,OEC'_+F(RSC^O,V?Z[/
M'80IE2R#3H5TFFBG94UVZ<TTEH9BH<I72Q`06;@8%!(8@',220S-&IIPIWU5
M.+D2.HYOU)L?8R?\8^0TY>\GY0B'M^YY5N66GK'D#*4\ZN,Q,UB16%&+M5$:
M2IA8PIHH3@R=`@D*S0P)F3.5-4H%;;ELIU.\8/P2W;'1@!O[,A6>^WQ\/'?6
M@]HX9+.%>.=5^?=E`0H7O#3KN[*"1"#YX0\Q-.')-P^VKY6BI9!X<I_XT!C7
M2:A=^AB;>6LC]G-I=FMIKA]U`[E^@B'G^8ZTZU)]:QP$NA"-"$:$+@H<J::A
MSG*F0A#&.H<P%(F4H")CF,(@!2D`-Q$?`-"%61PWR%RUF7W!>0O-V@<4LK\F
ML:49O(<9\#2M$G:5!0M;95MTC^KIE-2XR[`SAY93J'6[VQ1*1)[VG'^$`K5Y
MDNMH)`%/3`JX(J1`.>UI..-5C_N[SF?>6/&E)W8_;_SIB9WA2=-D4F1K';,9
MSL1"5DK%=C;VS]A7)QY,K-W3`R2HBD0P)F;@8P;`.EFK2ND@!/M:0S8N:6D<
M"G__`-O5R5_J)QKMW'J;D"+6/`]D^KKR*B@G66QQ=EW#^/*B01$PMX:PIO6^
M_@4BJ8>&VF03M+2W&M47T8$@>WPD*PF&KK/$J"74R10P>X&N9EGFNN!*':;'
M4,!?4(8Q#"G/V+NZ!L!@+WAON.P>>OD]^.4NM_-JPNAA79H&@G*OWBZ/VKU#
MY,ALW25Q$T'6V[>X]E.7'\4W&.[JY?BV:24TO'0;42&<F`PIM4$?^XU8(>DB
MZ?*A\J9>T1WZCT`1UTAT/U#*^YY%W/+;6;CHE?#(6O+!C1K<`<\ZA<JW>P'*
MYMO%&Z]>W!SCDW'#+AB5NFQNU$N]6F8^SUB)=8^K<:@WB(1X1-1^\GWJHE9.
ME91/L=(2:A4E%5#-SD[";AUZ;^P=LZTZ1ZJZ;N-FZALXINA=M@`@AE`?)/<C
M.:60FK2YI:-(+@-->*Z>GZ>W+:]SA_VZZE&Z3/U/.3`SL!QKB*`$<5]5=J.$
MJG,UO[+6T4I:QU<LK$/Y:6D)9O$6)T5P$<D@TDG#AH!/51$J9CE,8IMNOPFZ
M:V3R;Z8WJUDV+:&VV_[MMHN(97OYL5O<1N>6EL;CI`.D#52O"F"9N%SU5N%G
M/]YN7\N&Y,5&X$L`:>`'Z1/>FGR-DMO;$C.ECDAKK'$]!51D<6K6?20_E[CZ
M1B&93;42;;;^FN4!`!*8``>J.O/,M_6$8W*X<ZPZ_A<637$)TQR",EK2(ZT-
M1AD.Q<BZ;Z:.VS,,;6SVL@#G%^#FNX@9U;0"G&M5HG?+>^F5%0D%S/'!A,4'
M"VRCI,"=Q1*HY$I%C]H=!!03"'AKR7O^\76^3WC[Z7F708T:RP,U_4<Z$U=W
M^I=Q[9:LM[AC(6!D;JY95IF5.YQK342P)B@BI#$.%,B#"4P;#L=$5"C^TI@U
M]N?)`.'E'L#7`APV]F!SS*\<=8#3U3?M[+E_JSX)ZEUD6Z2JSA0B*"*1UEUE
M3E32113*8ZBJBAQ`A")D*(B(CL`!OKM(F@KP7&^-%7^X+2?_`-Y/<MY/<VW8
M_<\6\?F2?'KCX<X][(ZS@%TYVR1X'W)ZKJ-3<N!,7<0"7+UZ!J%KF22ZP#AA
MZ>G!6"71Q<L\356!!`!WV``\OP_N\PU9D8VN7!50=6)JJI/^X[XX@W?85Y2P
M3(4@>D7P_>W;8G:)7*(.I^B2+E0H`/JB0'[4IA\BIE^&J$\=)6O;E1:>WR-C
MJTUQ^5%,_P"U7R:0Y0\*L26]](IOKM48LN-,A)^JF=VE9J:DE&HNWB8&]0AI
MN$*U>%,8/G]8=A'8=6HR"SO]/3V*M<1.CD.K(XJ18P]##L/0!';;J.P#T#\1
MU+I.FO!5"[5](K542/>J,!O=,NP`(?*TP,!AW#8!_3E?.._7IL4P:S;AP=<`
MCL^U;L`UV.'"H5Y9U!PUFJ;FO6"-:3,%/5\\/,1;Y$CAE)Q4C&_2/F#I$X"5
M9LZ;+&(<H]!`PZT&Z"VA&-/L"QJEKJC@J+'*7$65O9YY\0%\Q*N]2I9Y9>\8
MAD7)ES1MHH#]WZ5FQC852"`.U(M!P:/<%-\PHF0<`&X@.J+V.BEU,R6Q"T7-
ML7.I@:?!73.,/(S'_*W"%(SAC9Z"\!<HTJKF/45(I(5FP-BE1G:O,%(.Z,I"
M2'>D<!`O>0"J%#L.41O1OU1U[?@LJ1FA^D_RJL/[_?"&SU;)K+FKCV+<.*=;
MVT)#9:6BT#&5IUUADTX^O7![Z!>Y&*L#!!!`Z_0J3YN7O$/5+JC/$[F<WA17
M()&NCY7%3G^U_P`Y*KS3XX5:75E&H9DH<5%U3,-9%8@2#>=CFI&3>VHMSJ>J
MM!6]%M]4DL4!(1<ZB([&3V&S"\2,J*X&BJS1/B<`[(BM5)/O^`_X?OU-118+
M@HJ1,IS'$"%(0RASF$I2$*4!,8QSF$"E*4`W$1Z`&FDTP3=0U:0HUN-G-E[R
MDYF<B,;XO?P<MQTX]TNM5]Y:FC0';NXYCG)Y\$FM$S8.?0"M0D;&+M"%3(8'
M"R8J@?M$ND#VFM,@IWP/C:'.ICZ8KR_=TY2K<8N'-X4K;X4,HYA`,/XO9(*%
M"14F;<D=G-2[)+<%.Z!KQUU2J%_TW)T0\3%`6O>`SC4I;:$RRT/@`3[^W_QP
M9\4^(V%\-$033G(BJM)N[."ALH^O5H*6<M"ZYO%4Z$@\%L4P]?20('EI;<-:
MPAV=:^]1RG4\]@P6U-LK$-=:M8Z?8FB;Z!M4%+5V99J%*8CF+FF*\>_0,!@,
M'\QLX,`#MT'KJ5QCTG#!-:2T@M5&_@Y<I3VV_=8>XONC[[;437ZP8`NKIRKZ
M+-:K6:2(:BV=T<1*F#=L]",>>H;H"2JG7;?68',;-QIQ6H87SV_,:1I'O5[`
MH@;J'A\?CTWW#XAUUI1FKEE+GJ=(M(^9G'>0S'7XRRU%`BUXJ"#E-LR.<J0S
MT*Y$57,6BJ<Q2$?(+D]5#?H81,01#N`=>2?Q4^1]QYH=/,W?8HV/ZBM6AHJ:
M5C:2Z@H"2:N-`NS_`"UZU;TM>R6MZZFV7&=,:/RJ1AA2F*AA<EL%1D%8J;CI
M2'>LECD7C91JY8N$%2B`'`R#DB8@;Y?$-^G@.VODYNVR[]TU?';KZWN;6[CS
M#V/&KAJ:0#5II0'#(X+U!#/MFXVK+BUGBDC<W,.&![#W_-.%'Y.51BVT6FX`
MJ";A9ZX+W_ZCM8A4@.??Q])$H%`1W\1^.M$=37\>W#:8GR-M'2:GT;)4F@%!
M]..`"SY]LLWSQS589&G$U&2R&9RTN[3B!([.4T9#,FB)RJCNF+4ZZQ!`Q!^0
MY#J;_$!UL[IU_NURZWN+22075I#'%#5L@&@.<YU2&X$AQIVJ"'8;/7,3HY<D
MI=F.(`^Q-Y9;VK-/5WA5=UGQ@7<=H_RP=F`#.5"[;=I55MU-O(3:XMOV[W.X
M;I)N%N92'D!K0Q^HX"I(T\75XK5MK*SMF:"Y@`RQ%`$X^$./E[SI:&(%CW\?
M4".TE;!:WK=5NS39%4`5FT:HN4I9*1=)@)2%)W`7?N,(`&NXO)WR-ZQ\S-_L
M7NLI(NG(KH/N)90YC2T!I+6DM.IU.&&>:XSU;UIM73.VS0\P/W"2/]4&4<0<
M1]6(H.TJ?V%B64#$1L)&HE;1T0Q:QK!N4=P1:,T$V[=/<?$2IIAN/F.OL_M>
MWVFT6$6T6#0VRMHVQL'<T#->/Y[B:[F==7!K/(XN)[22HXN8W''G;R/)=<>8
MVY.XOP?@^U,$8A1I#X[L$EE-_$N62:,Y'REP//)-6+:17%0@_0(H*&;&[!/U
M-O?<-32`1BB)T;35X-5JEPT]MGG'P29S%8PORKPG.X]M-D8V6RTV_8ALCM#[
MBDBUCG\A!2,79VTA&/GL2U(F;=0Z)S)$$Q-PWU%%"Z,DDBA/IP4\L]O(!]+J
MCU?-3N$`P%`#B`F[0[A#?;N[0[A#?<0#?4[B":\%3-*X*%'FEP'YV<WZ^]QE
MD+D]@JI8<3NH6F)J]0Q%9?O3A.)<NQJX3\Y)V9=9T[CFKD!5*W%%%1?<VPEV
M*$,D;GTH1I].Y2PR-C=J(-:K7OC![/\`S8X7621LW'7F_1X<)XJ"=HJ=FQ;+
MR])LQ6@*`T4EH0U@4`7K4JIBI.4#(N4RF$`4[=RBSE2@U8YOQ^2LS7,,P`+7
M5`[OFI;,@53G7+8LQ[$XZRUQ[J67D4'R>5;=,8VMT_4Y%80`(UQ0JX>R(N8L
M2"&ZY7ZKDIA'Y>T`VTX-GTD5;6OL_(J8Y>JI!HH.<M>P3R*SWD6S9?R_S1K-
MIR1<'R4A/3O],Y)J0ZK1NBSCV\>V:S[9"-81C)LDBV12(4B*:90#<=Q&M]TE
M,FM[FGW_`"5QMU&UNAH<&>Q3!\7</>X#B:4JM<SER5PYF_%4%$K13M4F+IJM
MY3=$:L#-X10;(VFAAGJR"Y$_J57+4ZJR8#N;O'NU>:"&T<054E<QSZQ@@=_:
MLA]P?A!4^=V!)'%DL]95NY1+Y&Q8TO3AD9X>IV=ONF<[A)$2.7,++LCF;O$"
M&`5""4P?,0NT4C"\BE$Z*9T1PK0YJ,CBG[3/.SABM).<%<ZJ1#,IU9)U8*).
M8JEK%CV9>HD](CUQ#/[!ZC21!+Y!=M1;N#$``,82@`:9R9F^%S:>WY*22:*0
M@D'`>G%3AT>HW:;Q,WIW)`^.<B6J7BY&(OH5BLO6&/K(S>+.4@;)UFRO)EP1
MHO&'(1=)954AE`,(;`(`$[&T:1)0N)X9?8H"X!U65`4.=Y]E#^F>5@SS[?/(
M"Q\6+^FHNJ%4?(.;3CU=)PH*KF&*4R_W).MNS#L>/>)R34`V["D[2[5S"\&L
M1`]/3L5IMT"SERBK5LO7[)[Q-78DA;)C'A3E)\U(5$MT8Y$R'0?N?:7M^K>5
MX:W)I(*J#U,5$4B;[[%`-@TNBXXZ3[?DHW"S/A+_`'!,YFSBS[K7+FNO:3DS
MDI@?C=C:;1,WGJE@B#NT[8)E@M\J\9+V^95B)!5FHGN"B3==!%8![3E$O33@
MR4BCR/3U)S76K!4!Q=ZA\T\_"/VZY_@!@K,='PWE&"NF5\DRS2P1%TR#4'+*
MK1,E%Q*,5$L9.OP$T>2?1#/O<K;)NB*'46VW``TX1D"F%5')-S'"M=("T>Y,
M^T!S3YA7N!R5G3F[1WE@J(%"DPE6Q7,0].IGINT'I3P,0-B/VNW#MJD=PY7%
M5PN*9`.<Q2%`&NB<XU)'I[%-#<11'`&E/3BI@>--/Y@TY"3B^3N6\1999-HV
M+:UF:Q_09RD6-5ZV,=.0>6HKV9D8AX+IL4@A]*BA_-[A$`+L&I6-+6T<03W?
MR*F35Q/`E.1G2+SW+TPC3CK:\;4Z]GE6@KS&4:U.6JO)P@)N`?$;14#*Q#HT
MJ94R8I&.J*0`4P&+U`04@D4%*]Z!GBJ\6:_87Y&<CLI7+-&8.7E`D\A7F00?
M33N$Q5*QD80&;1LP8-8]DC8$@:-F+%HFDF`;GV(`B83;CJD;20R:RYOQ^2N1
MW36-T`'2I4.(?'CW`N/[JE4K*W*G%V=\+5MNM&.6\[CBP,LK)0S:)<MH1E&W
M0DX9!Z9@_*V`3R*+E06I#D[Q-VB%MC)`\8M+?CEZE!*Z%U2P$%2;:M*!=1R=
MQ@'RVV$/(>H^6HG%S7:FNX9<$8'Z7-!':O%E*U`S0D-,0<)+"0-B&E(MB_,0
M.O0HNFZHE#KY:R+O9-DW%_,W&RM)9*4J^)CS3LJ156&7=["-%M/+%'V-)`KV
MYKQ_Z<T/K_Z(IO7I_P"V8;P^'_@M4/X,Z/KAM>W_`.7C^2D&Y;N,KN?^D[YH
M_IU1/#]$4[;_`.-0X!_<#+1_!O2'_5[=_EX_DG#=-X'_`)<_]-WS2DQW14Q`
MZ=)IY#E'<IBUN(`0$/`0V9!L8!TK>D.E(WUCVS;P1Q^[QUK[D.W3=W-TF[GI
M_/=\UE#=HFV3*DBDBBFG\J:2"2:*:9````J9$R%*0H?``#6Y#!]W9R8"R.W'
MYK&!H]P50ND?4S2/D<36I.*^L-3$U.5!^7O*18K=[6A2*K.VMU'24JT@(YQ*
M.V<25H9\=HT3,LY42!ZZ9M]D$2"8VZ@#VATW'IIKW"-G,=X0G1L,CPQM-16'
MX3R:YS!0F60#5MS5XR<>OS5]B^>$=OW4(V6^F;2;OTDDT6ZCU=)42ID$Y03`
MH]P[]%:X/;J;D4/88W:79IRY603B8N2E%D73A*-8/)!5!DB9P\639MU'!TFC
M<OS+N5"IB"9`ZF,(!YZ0NT\#[$T"IHL)Q3D>/RQ28R[Q<//P3.34>))QEE8_
M;Y5`S-P=L<RJ`'5**:AD^XA@,("`^7AI6N#A45'K3I&&,Z20<.&*<;2IB-+3
M"O!"X]P;@'4-_#?S\/#S\]#07BHR1PJ@QNTIC;"/:`CVAMN;;R+N(!N/EU`-
M#AHS2-.K`+7S%V=ARG?<@U&.ILS`QV.%D8R:EYQTR^H7L"SI0@1;9C'*O4"D
M3:(&5.<RXCU`.WSTQCVR5T\#13S0N@8'O(H>Q;"Z<H4NG!I.(0D'2$4-"A)T
M\P_PTX,+A4414)0ZZ.6>Y"-_[=-(6D9H!!0'70&DBH15&D(I@4)=*&DXA"32
M$4P*$H:5GB0EU,D2#J)^:4)-,0C0A&A"-"$:$(T(6D/.2]FC*!`8NC5G03>7
M;"QKRB4<DHYDDZV@Y06FU&C5`!667==R3=,H?Q"H(?'5:ZD;R^1CK./L5RR8
M3-KPH`O2QADO($!ERKX(FZ#7:O4#8R//UA".E5Y.QPL3"*)1;(MH43*2,2>O
M13$%$D2B5-00V4/UT1R-81`X?73V>],F87!UPTU8'4]N>'=19ER4SA8L.U=1
M]5*TUFIM=6*91YYL[IO%.Y2:?F91\+&I-`!W-3;@$E%113,FF@B3O4.`F(4T
MTDKX7!@`)(K]B9#$R5A>30A/(XM:-5H7ZPOIFM?+%5Q"9M`(B8[2,<$8IKR+
M9OW")U2HNC&33#<1..P=1'2N>6MURX>I,9&7NT,Q*U;=\E;S&4VJYBF:K"PN
M-K?=82MPE;='?K7IU7YUTNT9VMP\*L2,:+*>B"Y&(('$4!W%0!$-(9&MI7B%
M/!;F9YB&#Q[EM#D"Z)T*HSMN<1KR6;P3!>079L56J!_IVZ*BZJRR[U9!NW;)
MD3$3G$3&#P*4PB`:2=SF,U#PJ&-@DET-PI@5&Y0<K9CP_CR'SQ9TX6S5/-N3
MDGLK$2+R=&U0T7.+O$(8T&=5R>':L$6;(RB2!4?F*<O<([@):[7R0,J^E''@
MM#E07#^5#4.:..`4D]ZN+"D4:U71^<`9UVOR$T83@)04%JT.JW1\_G<.`*0`
M^)M67DLBUR9'+[%FQ4DN.2WQ`XJ,[$V0<GXOXV6;+M4JU=D1D)R4R#>K%<7+
M]N:==R\JDU"(K#!@5-9T6*;G*"CI94J/J',1(I]A$*NF6)FO#22M69D$DXCF
M)\/`54G%.LGZDI5;MCQN$3]]K<7/N6RR@%)'`_CD7RR9U5!*!4FX*#\QA#8H
M;CJPPN#1KS.*R2UK'EK*D56NV5>1\K6,<V'(]'KL;+5F-52BX*<L,@Z8%N<R
M^=A&LPJ$6T9KN99@1X?N!94[=-T1,WI")?YFD=+0T:IXX=3M#O$GOKTW<F6-
M8B=N,464NYX)D\EH.LM3HIJ33PB8C&,$'3E<R";=58$U#J*F*0"'.(]H;:EJ
M0*OS3"P<W0#1BU$HW)?.N3PRG#4''E*FK+3+"Y91KH9>11JZ<:S]9)1LZD5S
M(&E9I\Y2`K4J?TR9B@=0_:4"@9@D<^IBR&"M306K2WZB,.Q;=/[=88"AQ\].
M5XAK2I&,32L+'.A&*C999KZL@9U,*E.FQ@XH4U#KNC@8")DZ=QA*`J\R,CYI
M\(5-K&&X$+#])XK1R-YCY2EL)WO**%1I+0M2L#MBE-2#N90K<BU%PU;1D1!M
MA-]QG+`Y46,8YN]!NDCVB<0.(D"H^Y<6<X>#+T"T)+2W,PB:2'T]BS@O)S*K
MZ2X_DCJ%`-6^7WD>W=0TB]DALRC%-HU<6*RQC%,$THNLL15/]*LZ,HJX*3O$
MI2#N,C)G@`<78A1<JU;&X5<7@]F"W<GIZ(K$/)3]@D6T5#Q391V_D'2GIHMV
MY-@[A'J(G.80*0I0$QSB!2@(B`:LBOYRHBJU,RKGW)L$WH36D4N&:RF4K.SK
M]*:6YV^4L2K(_:NZL<G5V*+8&$<1D(&])1X5=/O*)RE'<H1OD+'!HS(JK$43
M7M+G9!;B-@7*@D5R<BK@$R`NHF42)G5`A05,F0PF,1,RFXE`1$0#S'QU(*_G
M*%U*X9+Z`T]GB34NIDB0=1/S2A)IB$:$(T(1H0C0A&A"T-M+.UH<MWUWL&,K
MI<X>MT)C%8C4@8Y%S!EFWYO5F7+^5=KH1\,X(994HK+&`4PV$`$0#566)[Y@
M\>$!66O:+<M!_6EWPHM@<7XSE(6>M.3;VNT?9*O!&K9\5B<ZL54ZTP$QHFGP
M:JA2G6;LN[O<N!`OU3D1-L!0+J3E&NHXN4;WUCY;<L_:F)R5!9*R%R;J[8E*
MD'-$Q?"(S=5EY5,R5*=7>6%$5)Z7<`J520+7V@"5!J@!E3.$@`1(4YC`UT<K
MY`XTH!12QR1,BTBNHYIU>5E$L^1,(V2LU9!9]++.H%\XC&I@37EHZ,E6KJ38
M-0$P`9PLV3,8B8F'O,4"]1'4DS'21Z6YU3;=[62ZGY)M)VASF=+KB^)-6YBJ
MX1Q&>.G%!L<:O"2=VLD<V2;Q4;'0;PJ+]M#1!4@!5==,@*"8P$`0V$6.C<XM
M(\(;3VJ6.01-<]I_6$_!<^;UCD5*#7L35QL]?67+]E9P!(^,`%)!:O1ITI*<
M,W3,8I0,H5--,-Q`INX0^.DN758(QXSBH[4M;)K=E]JY3F.G>:Y[$]5;5R<K
M&$<1.(V=>GL<8XK\A<)Z%9D90,%%PCTJ4BG$QA"&.[<JIID4,<2I]W\6B>)S
MVM:,A12"3DZG5_6N/#L6:<IJK;\B5.JXPK,5(N(Z\WB$9W:;9`4S:OT^/7"1
MDG+XQE$Q2(Z42(F3M`PB(;:EG:9(@QOB45N8XY#*XXT6,3<#*YBA"X,8XULV
M-L<U6SQT789B>0:,V$]3:LL19BQJ!4%3J/#6)9LF"B@D`J"'<8QA.8`TDK2^
M$1C,)!(6S&1V)(60<L6UU)B%M7<>5F;GD96PUJ"L<554CGE"4@B^\HT9$2$#
MHIO&[<C4YP^4B:@]WR[Z'-):*9@41"6:RZ0T3!7NMYEOV:L0L'&+W\;C6FQ!
M+-6*L<S<:Q$SC,AFL%^NY9HJ9B5Q%';HJJ-&WK'31#T4@.8YSA&Z)YD#@!I`
M5ILMM&#B2\C.BW3RP_N4-BBX.:G$N;)>35U=G#L(9+95U.R"!6(.VR*RO\E!
MLLN9?8QQ$I"=1'4[Q5IIG19\9I)5_AK\%C?'#$:&&L45VJJ)$-8'"(35N?;!
MZSZR29"N'XK*]3JE9B<$";B/RI_B.F0L,;2#F3523RF1X+<@*+P.4$=D*U4B
M.QOCR*D%'&1YIK7++9&A2`TJ=2,8BDU(/53J$]/ZEO\`RB``")@$P:)P]\7+
M9Q*6V>R.3F29C*B:2SX'7LUTQ+A%E6)")X]XIBV]IGY%4I4V%XLY#=D?$&4!
M3O>*BH8ZSPQB_P#64`!#Y=1\BKFM/[(-Q]?I1/,NH%X_:D_!=F,:[DBS<DK]
MDBPT9_`1E><I4*D.[&V!K$Q-`C?7*\/5&B:A5GDM97!$Q]8I2M6[<Y^IS"!-
M,;#+S"XTT<,>"5[X^6&CQTQ]:RWDD>].;_A".B\?V6_4%I87UBM497TT#(NI
MN+1(6KH3:KI1)DA&,WJPN1]<P)&%/<=Q*`:DF+PX:15M,?>E@$98[4:.394J
MM9LM/*:R7B]U!9).K,64)2Y)^4X4>M0\AZ:\TK!*F.FXG9I5MNW(HD4"&75.
MH<2$(4HQ-CE<_6Z@I@I'/@9%RVDD''UJ0\/^S\M7%12AIS/$D2ZF2)-,<TDU
M"5&VFZ"BJ-M&@HJC;1H**HVT:"BJ-M&@HJC;1H**I.W;P`.OC^/41_XCHT%)
M4HV\NFC045[4NVC04M4FPZ-!25/!<1*(%-V@7NV'MW'8!-L.VX[&VZ^>PZ-!
M2@G(Y+4C^E679KD77LPVMO0%ZW68"0KE?@6,_.JR$(63.(.YXIG-:2:/9-9%
M10HI[I%`H@`'^7?4+X'ND#\*`45H2P-A,8#M9XX+;G;?QV'4V@JK5&WY>&VC
M04E3P1V^&^W3P_#;1H**]J-A_#1H**G@D`@=.@=!W#;R_+1H**]J7;?QV^.C
M04M4;;:-!15&W7?S_=O^_1H**I!(`^0?M^/CHT%)4\$O;X>'3P_#1H**]J7M
M#Q$`W^/GI0P<4M4G8'D`>._[?CH+.Q%>U+MI-!15&VE:P@U0EU(D1H0C0A&A
M"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(
+1H0C0A&A"-"%_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g573228ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g573228ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0`#>`P$1``(1`0,1`?_$`*L```$$`P$!````````
M``````D`!@<(`P0%"@(!`0`!!0$!```````````````'`P4&"`D$`A````8!
M`P,#`P0`!`,)`````0(#!`4&!P`1""$2$S$B"4$4%5%A,A9"(Q<*<8&1H;'!
M4C-S)"66$0`!`P,"`P4$!@<)```````!``(#$00%(08Q$@=!42(3"&$R%`EQ
M@9&AL15"4B-SP^-4T?%R,Y,D5=46_]H`#`,!``(1`Q$`/P#WHVVX0%(B%INP
MO2LV:7M(&PG7<K#L!$&R)?<JJ<1#]@#J(@'74;]4^K&QNC6TYMY;^O66F(BT
M:*<TLTA]V*&,>*1[C04&C1XG%K02+KA\+D<]>ML<;&7S'CV!H[2X]@']VJJT
M^Y>,@>*I1-*<O6@&[45W4N1FNJ'H!C-TX]V1/N^@=XZYEY;YK=E)F7V6SMDW
M=_CN8B-\U\V"5X[S"RUN`VO$#S":<5+4'1F7R`^]OV1S4U#8RX#ZR]M?L6=#
ME3(+[=N/0`!^HV3_`,`AM]9Y@_7_`-1,V`]G3ML,9`/CRQKKPT&/5"7I191&
MAR9)_<?S5MCR?D0#?^@E_P#T)NO_`#_"ZRU_K7ZAM87?^%@J!_RSO^O7G'3"
MR)I^8N_T?YJYZ_*Y\W_GCSI^I;'OZ?0?_IN@]-1YN#YBV_MN<S[SIR70-%>9
MF6J/L_+ZKV0])+2;W<GK^Y_FKLU;E?6Y6038V2#<UM-94J2;\CP))JB)N@&>
M?_%:*H$[^@F`IP#U'8-]O3TQ^:/T_P!S9UF%ZCX.YVY!+(&-N6SB\@82:5G_
M`&,$D;:Z%S6/#>+J-J1Y,OT?R=I;&?%W#+IS14L+>1Q_P^)P)]A(]BM4V<MW
MC=!VT62<-G*2:[==$Y5$ED52@=-1,Y1$IB'(8!`0]0'74''9&PR]A#E,7-'<
M8ZXB;)%+&X.9)&]H<Q[7#0M<T@@CB"HBEBD@D=#,TME:2""*$$:$$=X*SZ]B
MII:(N-8;!"U2$D['8I%M$0D.T4>R4D\4!-LT;);=RBA^OU$```W$QA```1'1
M%SZ7=:OD2LQ-QIDRUGJW.-4WD9*,Q/X7"*A0-U(H5-5%4F^QR'*4Y#`(&`!#
M;1$Z=$7-F)B)K\8]FIR191$1'(&<OY*1<)-&+-N40`RSERL8B2*11,&YC"`=
M=$4/(<G>.;E<K5OG/%"KD_\`%`E\K0K&^O1/\CW#T_;1$E^3O'-LN9LOG/%"
M3@O\D#WRM@J'T_\`3_(]W_9HBWX?D1@:P/2QL'F7&4K(&$`*R87:O.70B8=B
M@"";\RG4?3IHBF(AR*$*HF<JA#@!BG(8#$,`^@E,41`0']M$7UHB^%%$T2&5
M54(DF0!,=10Q2$(4/4QCF$"E`/U'1%`=JY4<=J8Z483^7Z.A))&`JL8RFFTM
M)I"(F#=5A%"\=)AN40W,4`W#1$R"<Y^+@J)IK91:,@5;@Z36DH*S1S8[<V_8
MJ5R]AD$.U38>WW>[;IHBD>I\E<`7F08P]3S#CZ<F)-<C6.AV=GBQEGKE0Q2)
MH-8U1P1XNH<Y@``*0=Q';UT13?HB6B)L7&Y5C']:EK?<9AI`UR#:*O9.4>G$
MJ+=!$ACF$"D*=594P%'M(0ICG'H`".B+HP,]#V>&CK!7Y!M+0LNU3>QLBS4!
M5L\:JAN19%0.ABCMM^PAHBZVB):(A^<P9)\-OJ,*5=06(P!Y`K7O[4RO#R3Q
MH9QV_P#G%`@%_P"`:X@_-&ESV;ZN[4V9;2R.Q+L(;@0_H"=UW/$Z6GZWE@-^
M@+8GHS!;LPMY?%H\_P"(Y"[MY0QKJ?175097(A%04O*<2D.<`.L)1,!3#TW[
M=@$2EVZ[=?T`=8)T4Z(XO'Q137$1\]X',]S>8U.GV5[!V>U9CF,G(*AO9P"L
M/7,<J.=DG92D1?M%E8J5*8!8&5;%,L<#+`($*95-$R?:80$IAZAN&N@VU.C=
MNU@AN8XQ%+$70S:>7S-!)%>`)#2VA.CM2*A1GD=R<AYHB>9CP'L_2H=.'L)!
MJ.(3F+CEL_;U]%%TQ*N"+TLL"3M%0Z`(.G2PF-V'-_F';)@!`#?<1#6=MZ68
MK(6UC#$Z#S0QXFHYAY0'O/9Q):*`:ZD*UG<4T$D[G-?R5;R5!%:M`^P'4J.+
M5356I7#U1'[)B*ITF'F3[7#U)(PD3421-N<0$I.XYQV)W`(`.^P:AS??22U\
MJ:ZGA;#8EQ;&'"AD`T!:WMT%7.T;6HXT"R3%9T2%L+7<\]`74X-)X@G[@.*K
MY88X$.]4OM,`]2AT[P$N_P!!V#<?^NN9O7/HO:P,ERF+B\N\;4T``#@/9I71
M2?B,@9*1NU'X*_\`Q9F7\KC5-%ZL=<L;(.VK45!$ZA$176/XC'-[C%3$=BA_
MA*&WTUU+^6[N'-YCT^1XW,2NF;CK^>&(N)+FL,LCN0N))(:?"P<&M`:-`H!Z
MLV=O:[H+X&AIEC:YU-`30"M/;V]YU5E-=`E&"6B(2?R.9#NF156O$G#*?Y2U
MRT`_O^4/MES]D)1H!H#Y)A+D3#O0+*NG#5=(W7N%,I?\6B*!OA\Y)IO0L_'B
MQ2!BK-TE[72$79U$Q32,Z($]%)E6[MW*KN1!8J>X"!$C=!VZ$1Y=$6)=!!TB
MHW<HI.&ZQ!(J@NF15%4AO4BB2@&(<@_4!`0T1!`^7['V.:=BZB7"O4RL5VQN
M;NVB'$O"0[**>.X]>-DG"C9V:/2;`Z)Y6I!**@&$FVP"`".B)U?$GC#&=GP-
M+7N;I-8G[2[NDO'&FIN&82[UNTBUUTFJ#-201<F8D`BH]X)=GDV`3;[!HBL_
MS1XKX<O.#[]--:/5ZS<JY".YV!M4%$,H-^A(,R"8A)!Q%H-E)!BH4P]R2HF#
M?80V^I$-#XF^4.0WN5%,"SD\^L5(D*W+34.WDUU'CFNOXA=BB1&-7<'.LC&N
MB/A\B7<)2"0G8`!N`D1Y<KY2J&&*!8\D7J0"-K=98J/7JH!WN%Q*`BFT9H`/
M>Y=KB'L3*`F'81VV`=$7G^@LN<A?D]S4ZH4)8Y/&F$XC=[/1\"HX(UC:^9<"
M)%FUT5FXST_*I@8$DE3E;CXS]I"@`[D1PL.<6L&X*BF<?0Z'#HR#9-,%[1+-
M4)>U/UR%`IG+J;>)'<IG4,'<)$?$D`C[2!HBFV6K\#/L58R=A8F9CER]J["5
MCFD@S6+L(;*-G:*J)PV'ZET1"ESQP48T#,6).0G&^JND']?R;67]SQY"=(Q:
M-3D".7$W%-C*)E8MVQ4S?=(%,*9P$G80-C;D1;4C&.DF<Y>PYDR&.0?4AC%`
M3%'J/\1';1%DT1!*^2W)-SR^^G^.^(D1E([%E0?Y:S4_:JBLV:M(=%T_B8!3
M[<?,E+H#"K*`B(""OF*7IHB[GQ$<DT;KCZ:P1/R)33V/EB/ZJFX4!-1Q59$B
M@?BV:1C"=4\.\8+JJ[=2E<!OHB,SHB6B(<?,-8I,FU!,3@7>EF.(#MZ!-R'4
MHCZ#T^G7;7'[UZ10O]1FVI)F@ENU]"16A^/N.'M[EL=T@:X[5O"/ZW^$Q-O'
M#MF11(RDY%-"#XP%!]&/I%$_IN0J*;!R4#B7U,42FW]#!J3.CHL8H8PZ]MHX
MR!5LD4DH/>.41.`=Q&E#[5][DCF=S`0RN=WM>UI'UEP^^H]B>>5K6I%3E>K:
M`D802[()4R+--\R92KH3F3^\^U?#YNQ,/9V_PW+OMOK(>I_4!V.ZB6>R)'BU
MP(M6W#6,$L<=RXD`R\LFI#:EE!X0YM:55KVQB&W.-GRC@9+X/Y*N+7.8*>[5
MNFO&O'ZE*-0LU.2BA!V*9EA2`2F`Q2B"NW00]/I^_36P>UMP[5&+'F%O-RZ:
MCBL2RF.RINJQUY:_<N@]F(Z8KSJ55<1S<S9[^.:RTM'R$L"K8J`G\3<&Z3EN
MF*1R]FYDQ#8OZZK9#)8_,827(RN@:Z.;RFS31235:&UHWE#VZ'PZM/#O5&&U
MN+2^;;-;(X.9S.8QS64->)J0=1KQ[53>^/&Y5%S$E$'PBI[1;HN4$BE'J82)
MK(-RIE`>@%``_8-M:"]:6VDD$I\^&>@=H&N`I0UH',:&@'LT`HICVY'(>4.C
M<P4[2"?K()K]*N)Q"5*KCM^)3`8`FW/4/_<6Z#^__=K8CY>,<472;(,A]S\W
ME/VN>5%?6!I;N*.O'R&_@%;#6_JB91;FO+-6P9BRZ95N;Y&/@*=#JR+E98P%
M*HX4429QS0NX@(G>2+E)(-NH=^_TT1!HX$\FN.B7^K/([D!F:@PF7L\6*4%2
MM3TJ565I=";OW!8FJ>3Q&'\:NS2:F*F/H5$H#Z:(A4Y_R?1>.G.#_5SCI?H6
MV4LUK0OL0_KSL%V+()Y116T5PS=/M(FUCTI)9!`A@$!*0!VZ:(O8#BW(U=RY
MCNFY*JCE-U`W2NQ-A8"19-8[=.48H/!9.12$2D>,A6\:Q!V$BA1`0`0T1/[1
M$$#YS9$([C]C=01V[\H1Y-^X0]82=';H(?IHBA/XO>3UDQ-Q9G3-^..<,JUZ
M.N5DDU[5C&,K<TP(!G"JKMHJSDK'%2GG8```;QI*%$-QWZ=2+7R)\FS[G,]#
MB=A&'BL)*94\U=D;YF*<(S=>`QBE6K\7'03>1!I,O]^XAQ6,8H(F*!?<(@1$
MSX3\`,?<06#N;"56O&4IMD1E,7)VW^S;L69ME',37F/D4.UCW"Q2BJ90QE%O
M$F.Q-A`2*F?SF7B;K^%<8UEJ+A."L5T6?RRJ1_&B9U"MDR1S=<2F*<X*EDEA
M`O\`$>WK]-$75^#>-B%>/>0+<U1`)F=R`XBY1SW%,99I7TE0BTQ#;O`$?R2V
MVXB`]W31$;?1$M$2T1+1%7WE%R`K7&3"5UR]9E4.ROQRJ<)'KF$@3EF=)*D@
MH-,2B404DWI2I@.X`&^XB&B(6G`;/O%>@8MM%]S9G7':N:,^3+^UY);S4DF:
M29QSH/!%U*7(":J:HQB?F,/782N-MM$0>0S-4>'G.,][Q!<V-SQ="W$'S*5@
M7RKY.7H$VNB-@BU3$``%\9$'"8$`#=I3%'Z[:(O9G4[-$7.LP5L@7B#^'L,6
MSEH]VV5*LBJW>(E5+VJ$$2F$@F$IOT,`AHB<&B(5_.Y^9ADZDG*(AO2-S`&_
M\0GY+N^H!U#_`)ZXF?,IS#\'UZVO?M)#&[:-:=QO;E;3]"K<7&UKYI_KOX3%
M!E&R0XBUT0:N4&9S"7=XHBFL9(!#^0&736.3Q@.X"0`/TZ"([:LO1_J_\+'$
M;:6.-[BWQN:'$`T%1S!Q`!U\`#J\%E6?VTRX:[S&N<W]4$BOV$<?;IWJSO\`
M9*%DIBC'6HS]TW@VJTBZM[A\<+$DL*:B+9K#`)E4FK%=ZH1/PJ`<IBF$X@4P
M^W;O+NZ9]9,?'9;L-P9,=&9?S(2\EY&ZA#60$\S6Q/D<&F*0/:02_E8_5L9L
ML\]MF=T^,#&NG<&B`-K"1H29.!+@T$\PH=*5(XZD73<=1A*P\D+9:%8^QE?*
MIL!4:-SLBHNG;!J#IRF"IET5GJ!/(8`)VD,.PAMOKR8+IULS#-Q]QD=PY:?'
M7H>6Q'RHRP,>^-G/(.:H<]HYR&MHTFA!U52[S6=NC<16]G:MGMRVKO$>:H:X
M\K32A#2:"IU"R6K*[.,CU(*'6-7%845F0,VK@[FORZ"2QP!P9!R*J9'JQ@`_
M<8#$5_EON8`U>]T]5,;A<<["XF3X!UIS1AC7%]O.T./B(?4>8X^*KJM?J0:D
M!4\7M>>YG%[=M^(;-1W,X`2,)`TJ*'E'"@U'#L50+==QD5%E#BEYC&[C`F1-
M$ACF$-^XB12$*;8=O:4H!KG-UEZJLN&RELC?B7<P\(`&M>QOA'U`!3)@L#\.
M``#R#OU_'7[42'A"L+C%+M80,`'G7NPB`[#VKN"B!3>A^T0V']]="OEKRRW'
M1&ZN9:\TF5E-3[7/6OG6]@CW6Q@II`W\`KEZZ(J&4`+GAD&0YJ<RL2_'IC.7
M-_4:;+-LC\@IZ/5(JV8$B61W4?!N?`J)'\>H9Z5JZ1'W(O3DW+N01`B-G&8:
MQ+#QL?$1^-*(@PBV36.8H#5(-846;)`C=LD*JS%193QHI@'<8PF';<1$=$0P
M?ERX>UO*/%.QW''=-A(O(&(U$[C$IUN&CXQ[.Q28*,I>!.+)L@51`R;\'8]P
MAL+7H/782*E/P'<T$+-$6GB?;Y<!?P2+BYXP^[53(+B(<OS*6:)*LNIYG#DC
MZ614;($$0(W24V``#1%Z7M$7G^_W",G^+XUXL6[NT#Y<C4]P#<1W@+"/ZATZ
M:(I#^`Z0"4X5R*IC`H'^J5S3$H@'I]\H&QB[CT$`^OKHBJ#\R/Q[/*>,IS(P
M!%'9-&;H\QEZK022J2L8[,L+T<AQ"2)MTR&=BI^0(00V.HD*1.WNV(K1_$E\
MI$1R5K\=@/,TVBTSI6HY%"OS#]42%R;"LB%;BZ%=4Y@-:&H>(7)!,!G1E1,F
M7VFT17:^2;B9(\O>-4]1JH9LCD2NOV]OH:CDR2"+Z:BVSM(()V]5,4&;"5*Z
M`5#AN/<D3IHB\]_Q)<V4.'6<+QQFY))O\=0EUF&<>9Q;6JT4%"OD4N\;`VF2
MN?&6.C)PK\WF<J_Y21FY.H`;1%["6[A!V@BZ:KHN6SA,BR#ANH19!=%0H'35
M153,9-1-0H@)3%$0$!Z:(LVB*I',GF+BSACB27R/D&49*3)V;U*CTH'A$9J[
M6!)`3-(J/1*"JR391P9,BSD2"DW`X"80W#<BEW`]WM>2L.XZOUXKC*HVRVUA
MA.3=:CWBS]E#.WP'5!DW>N$6Z[DB:(D'N,0HB(CTT1!/Y`WA/Y"?D4Q[Q*K#
MC\C@GC8]&[9H?->Y:+L-D;.&SI>J/E43*(+MEV,>DFS5#<"K*+;^FB(Y26)\
M7(I)(IXXH@)HI)HI@-1@#"":1`(0!,,>(CL4H!HB"U\V7$:"LO'9MF_&]4AX
M:SX;77>SK>N1#.,-,4^058A*.'Y62*"*B-9:-UW11,`"`'-U'H&B+E_!'S$;
MY9PU,\=+/*D5N&'E$W56*Z6236?T&7[S-&C0BAO.^<Q4HU>*+F#N$B2Z>^P;
M:(C\Z(JP\E^/*&<(%HO%O48BY0)%!AWRY!,U>H&$QSQ+\Q=SIME#*'$ABA[5
M#;CTWUIYZN/2M8>HW;L%SC9X[+?>-:[X:9XK'*PU)MYB*EK"7.<US1X7D$U;
M52=TTZAR;'OWLN6.EPTY'F-'O-/9(WO(H`0>(&FJ$O8N/_(.F/UV;O&EE?D1
M4$"O8%F,W%+;ALF=)ZP,LGL<-C;#L8H]!`!#;7'')>F/U-=,\JZUEVSE+B*-
MW^9:,==0/UT+98>9HKQH:'O`-:;5V._]@9N`2QY&VC<X>[*[RWCOJUU#]?!?
M+&J9X:IF0_TPR`"9^T3E)7GX`IV["`&`J8"(`8/0>G3?UUGV%Q_J&LH?AI=J
M;C;$=7`6<]'$<`?"-!Q%>WVJC<9#8TKN<9*PYAP_:LT^]=A>'SPX0;-U,7Y`
M%-HD=)`/Z[);$345.N<H;D]H&5.(CM^NLHN)NOUQ;16\FU-Q\D+"UO\`LYN!
M<7$<#VD\%X8Y]CQR.D;D[#F>03^U9Q`I^`3>D*9G=Z8PJ8RR`I[2E`QJX_,/
M:4H%(4!,0!V3*&P?\-1]N'`^HO,-+6;4W$-!1QLYZZ:`>[P`%`KI:Y38UOPR
M5@->R5O]O:GYCKBAG;(4FU+*5IY2(4QR'=R]J1%@9)MN'>+6-$3/G*RA>J8`
M0"B80$1`NXA5V!Z)/41U7S41W!CIL'@WN!EN;\&$LCKJ8X"#+(\CW!RT)(+G
M-;4BU9_JOL;;ULXVEPR]O`*-C@/-4]G,_P!UH';K6G"IT1FL;8_A<84Z'IL"
M!S,HM$WD<*@7S/'C@YEWKQ3M#VBY=*'.!=Q[`';<=M=W>D?2W;G1K8-AT_VN
M''&V3#5[Z<\LKR7RRNIP,DCG.Y:D-!Y02`M.-R;@O=SYB;,W]!/*>`X-:!1K
M1]#0!7MI50;R0PGGW,*T2SQ-RKF^.=<)$R$?9V58QA5[A8I]R[.((OH^TV*5
M0-6C-6QA3V1:*G$?>50A@#4E*Q(7V(OA+MN`\F2F9\1<\\M5O*DTD_1F;;*X
MVJ=K6G4I5X1_)I6!M.3RX2R;]V0%5!,<J@J`!N\!#1$;#&5>O%6ID1"9%OZ>
M3K<S*L$I=$JJSI9)<QUCG1,%<824LU8>%(P$V*N?NVWZ;[:(JS<E>./(;.3V
M2C*)S!F\&8YG(<8>:J%;P_4+1,NT'#(S.2^WN4_,D<,DY$%#"<I69C%*;M*8
M/71$)*F?[=>IXZLD+<:'S)R_4+77'1'L%8:_3X2-E8IVF0R9%VCMO82*D-V&
M$HAOL8HB`[@(Z(B]8BP/R>Q]3[K6[OS-E,O2\O%$8T6WV/"E/A9BC/"&3`LD
M^1A)])G<E!2()3$7*U[C&[A-OZD5`^0OQ`96Y:(Q*'(WY`LGW]K!/'+V%A8_
M$-'J58BUG`[`JV@XB;$%G::7L!=PLNJ!1$"B4#&`2+-QZ^(C+O$QI)L>.OR#
MY1H<;-/6[Z8K\GB.DV^K2"[?S]JIX.8G0*T<'%P;N5:JH'/O[A-TV(C(0%<D
MB4:(JM_F6F0)8E=9PULGEX)K"L[:^*R(VE912NHN9!I%HRJP'4^U(LJ1$#]H
M&,`;Z(@&VG_;T8L7S%/Y3Q=R3R3AEBZL*ECIU7J%98&7Q\Y4<*N"M8&TC8V<
MJ9FT$Y2M^XA54R%V$Y]]]$12./'''DEANQ-E,A<U[EG^AM8E9BG4;SBJEQ$V
M5[N@#-__`'F!D$Y)9)JFF<HI+MECJ]X"97V]2+3Y:?'1Q5YGI$=YBH0IW%LU
M,SC\C5!X%=O#)N(>Q$\FF@Y:2B")P`4R/6[D$NO9V]QMR*IV,?CPYE<86S>"
MXU?()-/\>LE"I1.,L^8Q8WR!@8]/VHM8V;:SJ4ZFBBD`$*B@+1N`!N!`$=$4
MY2N)/D^LK8T6[Y;\=*.U73535G:%QXGW5B;B<H%(HT2MV0I:)\B?40[D]M_4
M!#H!%3>R?!7!9CO3;(O*7F+G7D!9DUT%'#B0BX"JM5&Z2XKJ1S!@W=33*%CE
M3"(>%HFF0N_0-$1$^0G&G/N6U&T'C#F%:^.^.4ZFTKCNKT;&-5E[&Y=-RN4%
MI1O?):52?Q9'3-1),46S5,Z8I=Q%@$W0B'Y@'X7KKQ9MTY?<"<[<ETZV65`C
M>PO)3%%.M4?/HIJKKIDFHV6GA^]\:SE0Q3%524*)QV,'T(C;4N)L4'58*(MM
MH_NMDCX])M,VO\,VKWYYZ3N\LA^$9N7C:-\NX?Y1%3E+MZZ(J-\H>('(3DE_
M=JFAS3L.+L,7F&D:],8TJN&*:_D',%+L#1TI$O+S+SJLDX9/VZJA5`3:MU!(
MH)0.'0=$0W,:_P"WTB,.7"'R!BWFMF2B7.!4\D58JY3H!A(-M^WR(F,6>,DZ
M:+E*!54%B*(K$]IR&*(AHB*K`\?N5<?AB\8ZFN;TQ/9"GU8<*=FH,&4B,L5&
M9,IJ*>RR!JXC/+UZR.YF&9N6(+K%0%N+OSE*8Z92B179T1+1$M$2T1+1$M$2
MT1<"U3;*MUJ?GY!\E&,H>(D)!P_6`ATVA&K914%A3542(J)3%#8@F+WFV+OU
MT1#WX79LN^2C63)^7\L1?]<N$[)5O#57?F@:L$O#1S]0BL]^`\@OTY1P,=L4
M!66)V*&`HB&PZ(B1K+(MTE%W"J:""1#**K+'*DDD0H;F.HH<2D(0H>HB(`&B
M*O\`BYWDN;O]^L$CE''-YQ2NZ<,J=#4]J*LQ7W;9V!#MYJ61559N%4$4SIG`
MAC=Y_=[=MM$4OV.YU*GIMU;598.O)NU`1:#,2;./%TJ/^!N5RJF=8P?7M`=O
MKHB[S5TU?-D'C)RW>-'*1%F[IJLFX;.$5"@9-5!=(QTE4CE'<#%$0$/31%77
M)?*O$.)\GTO$]OG/L;+<TW#A-<YFZ41`-$2$.D[L<@X712C4'GD`$1-OWCZ:
M(K`14O%3K!O*0DDPEXUV0%&S^-=H/6:Y#``@9)RV.HD<-A^@Z(AU<L\OY1:9
MVP]@O$^0QK"]W^YD;RLTBXL7-1K;$[,0F7<P_,X%LVD/,<F_A`I>W^6XZ(K^
M5:XU"VH.?ZG:H.T$BE",WZT-+L986JX`8I2.SLE5`354\1MM]N[8=O31$Z#G
M(F0RBARIID*)CG.8"D(4H;F,8QA`"E`/41T1--I?Z._G4ZNPM];?6)5H9^G"
M,IE@[DS,B&[#NOLVZZBP($-T$PAL&B+=G[;5JH1JI9['"5]-\N#9D>9E&4:5
MVX,(`"+<7:R7F/N8-P+OMOUT18V-SJ,I-O*U&V>`?V&.2(N^A&<NP<RK1$XG
M`JCABBN=RD7<@[[E#;Z[;AHBRS=LJ];5CT+!8H6$7EG2;*+0E)-FQ6D':Q@(
MDW9I.%DU'*ISCL`$`>HZ(M!+(%%7F7==0N586G6+4[Y[$)3L8>0:,T]_(Y<M
M2N16012`-S"8``H=1V#1%M5RYU&X$>*52SP-C)'KBU?&A)5E)@T<``#XG'V:
MROB,(#TWVW^FB)QG.1(AU%#E333*8ZBAS`0A"$`3&.<QA`I2E*&XB/0`T1-)
MID"C/Y]&K,+?6WUC<-%'Z$(RF6#N249H^0%7)6C==17PI^(VX[=.T=$3OT1+
M1$M$2T1+1$M$2T1+1$M$0I_DNRG*/DL8<2ZM+LJY8>04H!IFP3#TD7$Q]&@C
MN7DR8TBHHBFW=`Z8)'*`F`#E*)?\6B*OJ'%;&65[=B'#^"(QU8:SAV=B;1EO
MDP[,X7)*OX5FJ1G0JG,"8K"136D5TSJ-V8"DV3:B0YS')N8BMO\`)CF2IXWP
MS'UE_).SW6^S:,/3ZPWF%(N.ECKMW:#Y_;BMP!XYJD0V.=8Y$SDW>$0W[@W*
M)$^N$>.ZOA7BM&?TTSN>?GB9BQS<JO%NHLMDLB+=RZ='AV[E%LHXKJCWO)&K
ME3*5PU,10O0P:(AQ8RRM`N,.Y<YD9X.RO&9,C3ULQ[AC%5A%&;FJPNVF)&#5
MI]<J:A5Q8O2?9$$RQ4$U`3;CW']_4B)+PBH]MP-P_IT1F%^NTE8F&EK+)HRC
MD47%;AI/OE&5?<G6.(,UH-DH5L*8"`)&)V@`;;:(AF<?)["\S$<I>8V3$(:Q
M5VT2U@H6&JC:'"=SLDBR.]>%39M(B<4E))6>5<-6WA!ND':F"GC`I=PT17]^
M.#&MSP-Q(C`RLDI`2+UU.WA2'D5114@(.1*$@S;R!%S@#!_]N/\`GHB!?&<-
MAZZ(J,X10QER!S?>>77(N^0M8QW=Y:RU'"M(L5A)"GO]4KS\%E4GJ2KA`\K#
M1:#IH'@3$R3@ZY1'^(`)%;G@%B9Q$VSD'R$2KI:)CW+=R6?XJJB$>K"C_1&*
M\JJRFWD,`)(MDG[9VB9H4"!L3OV*4!V$BA.X\XL79(=Y;OV0KBL7#6')=W"T
M["]3D'#:W95F6*CA)S9[K]HJ@[8U=($2`V04.BV'SG%83&*0!(G9\8<)5;Q*
M9/Y%OX:*97_(SU&0CXNN0HH56B4N2.\6CH2'E&[=)@5])>,1=M2F,JC]N3OV
M[@T11GS*Q\WY4\S:/QYH+M<\A`Q"=OR_;W;DTJTJL"1\",=#PB9P%C#RK<4W
M(G;@`*.^X@*"/B+L1%-QKQ9P/B2P-;E2,?1,5=FT&,`O<CK/G5AD&"@)_=C)
MOG+I0'KEX9(#++'+Y#B`;CL``!$'[,M/KG+WE->9"/M,A7L"<=G;N9R[F22F
MO,HG)$-]P\JE(?=&D?#QC.+.=JHV`QT555#+&.`I@4BA=M'8]7;9$YY7*K-Z
M=@>M)#0L$8Y3<K1CW+LB4KC\6%ND$EBOY2$E71@!TLJHI]^0W8)]D@T1$N^+
M_&D15L66>]J#YKMD6="0M)HZ(5C*M&)-4^^+KT`N"*<?+)QB;LYU'+83)F%<
M"^I1T10/9.<V,\J*96R+?;>H3"^))22A:9A*JO':%ORS.PZ)EGL_=CLSI.&=
M716%$B"1CIM2=JQES'*/:!$^OC%AJO>GV4.13^'B&5^R1(-7[.*KD"5K4J)4
M>QPSC*_$2*+9)@WL*YB+GDFB1C'(D9!0X[*AHB+YHB6B):(EHB6B):(EHB6B
M):(F+<L88XR)]E_?:)4;D,<;N8&LU?BYHS3W"82MSR#5<R1#&'<2@/:(^H:(
MG5%1$5!1[:)@XR/AHIDF"3.,BF3:.CVB0"(@DV9M$D6R"8"/\2%`-$3>LV.Z
M%=7<4_N%+JUI>0:HK0[FPP,9,+1BIC`83LCR#9P+<W>4#>W;W``^H`.B)W@4
MI2@0I2E(4H%*0``"@4`V`H%#H!0#IMHBCUIB+%;"QC;V6.:0UM'W#EV6P(UB
M'3EDW;Q3S.WB+TK,%T7;I7W**D$JAQ$1,([CHB:'(W#3S/\`B2SXG;WJ5QZS
MMR!&$Q.PD:TDI(\3W>1RP;D>+($;&<G*3=4IN\H%V#U'1%I8KXQX8Q-6J3!0
M5"J3J1H\%$PS"TO*S##/NEXIDDR_-.'@-3*$EWGC$ZJY3>03'-[NHZ(IW>,V
M<BU78R#1L^9.DS(N6;Q!)RU<(GZ&27;K%.DLF8/4I@$!T1,&3P[B::0K[66Q
ME0I%I5!5&LLWE2@G#.`\_@%<L.T48F;1Y%A:IB8J12@84R[A[0V(I$!,A2`D
M4A`3`O8"8%`"`0`[0(!`#M`O;TV]-M$4:HX6Q`W0GVK?%U`00M1%4[*DC48)
M(LZFL;N52E>QB47J1S#N)5.XN_TT1/*O5JNU**;P=6@H>MPK0-FL3!1K.*CD
M-P`!%)FQ10;D,8"AN(%W';KHB^6%7K,5*2<Y&5V"CIN:%,TS,,(B/9RDL9(R
MADADY!NW3=OQ3,L<2^4Y]A,.WJ.B+NB&_0>H#T$!^NB)IMJ#16</)5YI2ZFU
M@)E1=68@VU<AT(>55=%[72DE&),RLGRCDH;*"J0XG#UWT1:DOC/'4_7&-/FJ
M+492IQAT%(VLO:[$KP$>=J83MQ91!V@L&O@,81*!$R@&^B)V,(]A%,VT=&,F
MD;'LTBH-&+!LBS9M42_Q1;-6Y$T$$B_0I2@`:(H\;X5P^S0G6S3%U`;(6@AT
M[$FWJ4&B6;3/Y.].3\;$HO$S>4WM/N'N'IU'1$]8"NP%4BFL%6(2)KL*Q*)&
?<3"1S2+C6I1ZB5!DR20;I`(^O:4-QT1=G1$M$7__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g573232g08h16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g573232g08h16.jpg
M_]C_X``02D9)1@`!``$`>`!X``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#P`K@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/6=8\0O:RM;6BJ95^\[=`:\+'9G[&7)!7_KU.NAAN979EIK
M.KO]V8>O^K%>-]>K37NQ_!_YFZP\+VN2'5=750?M"9/_`$R%:_7*_P#*OQ%[
M&GW&/KFK1-AID./^F8I?7ZT>B_'_`#']7@^INZ-KBZEF&0>7<(,D#H?<5[V!
MQ\<5=/1_UYG'5I.&IM"O36FAC?06F!CZOXAL=%N=/M[IR)+Z;RDQV]SZ#I0!
ML"@!DC^7&S8)"@DA>2<4`<I-\1]`M)!'>_;+.0\[+BT="?IQ0`Z'X@Z/<1&:
MUM]2N(>IDBL9&7Z]*`-#1O%FBZ^2FG7R2S+]Z)@5<?53@T`;F1B@"AJ6L:?H
MUK]HU"[BMHA_%(<9^@ZT`8,7CF.]C\S2M"U:_A[2QVX1"/8L10!6N/B7I-A*
M(M5L=2TZ1AG$]MP1]03F@#L;>=+F!)HSF.1`RGU!%`$O;CB@#'G\0V4'B.VT
M-V(O+B)I5`Z`#L3ZGF@#8'W:`%H`\XBC>6Y=N"2Y]N]?G_O3JZZGMW26AN6=
MDG$A&S;]]#TQZ@U[6'PJBN9G%4FF]&7$M()$15?<$))./O>E=:H49;?H8\[1
MG7MD5R`I>4]<=%KSL1AK;'13J%/1XVCUZ#GJ3T[<5S9?%QQ:CL:U[2IW.Y%?
M:^1Y-K(7(SR:!GBOCW[3KK7FO6[G[#IMP+.(CIG^)_INP*`/4?"NLC7/#=C?
MYS(\>)1Z..&_6@#:H`\N^,RA=-TI\?-Y[C/?&T\4`=QX4`7PCHX``_T6/I_N
MB@#RGXA`Z9\2+>ZT_*W3+')A!R7W8[>HH`]?U;4X-(TBXU"Y.(K>/>P'?T%`
M'F'@_3Y_'?B*YU_7?WUO:MB*!ON!\=`/0#K[T`>NJNU``,`<`#M0!E^(-"M?
M$.D3:?=)N#J=K=T;LP/:@"71+6XL=$L;6Y(,\,2QN4Z9`Q0!=FE2&%Y9&"QH
M"S$]@.M`'A7B*XU%KZP\<<HES<DP*?X$0_(/Q`/YT`>WV-Y%?V,%U`VZ*9`Z
MD>AH`MT`>?V>PSDL7^^>WO7PM!6F>K-]C:OV>/2E*^:(]XW;\=,?RS7LXCF=
M#W#E@ESZDEM?Q);[?E.>!Q11Q%.,7%;A.G8?=L9+1"PD''(0#]:VQ%I4UT%#
M0Q]."C7K?;N')ZC':O*P>N,C_70ZJFE,[4"OL#RV8'C+6FT'PU=740S<N/*M
MU'4R-P*`.9M7LH_!7_"./H^K,7@*R/\`8VYD/);K_>YH`ROA'JDMO=7^@W0*
M.#YL:-U##AA_6@#UL4`>8?&?_D%:5D_\O#_^@&@!Q\1^)O#?@G3[U-,L9[)+
M>,!Q*VY`5&TL,4`2>!=-L/$,Q\57UTU]JV_:R.H"V[#H`O\`(F@#3^*._P#X
M0:X";L&6/?@_P[J`(?A,$'@TA0`_VF0M[&@#O:`$P/2@`Q0!QGQ#U*6WT6+2
MK42-=:G((0L*[G"=78#Z4`8_BF>TU7P8VD6FC:I$;=5-MNLRH4IT_K0!8^$V
MM?;O#[Z<[?O+)_D]XV.1^1XH`]$H`\XBD:&>13P0Q&#VYKX"TJ=74]I)2C<W
M;.]3(0D/N'[QGYX':O8H8F,ERLXYTVM4/C2QC*2B!4+D@?-D+Z'%;0="-I17
MY$/FZE6]OC(I^;9+T..`U<F*Q2E=(UIP*ND,9-=MR%&1G..PQ6.6ZXN/S_(T
MKZ0.XS@$_P!:^R/+1P5[<)XE^)5IIBNKV6CH;B3!X:4]![XH`[[@C(Z4`>,>
M+E?PG\3[?6HFQ#<,L[`#M]UP?KUH`]AMKF&[@2>WE$L3C*LIR"*`/-OC,R_V
M;I*<;_/<X[XVXSCZF@#L?#D4%[X)TR"5%DADLT5UZ@_+@B@#RR-[OX9>."AW
MR:;..?22+.`?]Y:`/6]1L[/Q/X=GMEE5[:ZC^652#SV(H`\T\$ZK-X(UVZ\/
MZZOV>*=\QRMG;OZ9!]&H`]?1@RAE8%2.".010!4U/5+31[)[R^G6*!!DD]3[
M`4`9GA+5KO6M#.IWF$2>5VA7&-D>?ER:`,/09D\3?$+4=85P]IIB"UMN>"Q^
M\PH`[HX*GH0>H/>@#Q;3IE\#_%6>V=PEE,_ELQ/"H_S+^1H`]J1PRY#`@]".
M<T`<]J_AXW4QN;5DCD)RZMT;Z5X>.RM5O>INS_KR.JE7Y-&9B:#JT>X>6F3_
M`+=>7'+<3#2/Z_Y'2\3!]"0Z-JI4*8DX_P!NJ_L[%K3_`#_R)]O2(WT#5)&R
MT:8_W^E2\LQ3WM^/^0_K%-&WH^B+IH:65Q).W!('"^PKV\!@%AM9:O\`KR.2
MI6<]"YJ6GQZG:BWEGGB7.[,,I0_3(KU4[,P3L84/P\\/6DGG6D5Q:S#)\V*X
M=6.>N3F@#IEBQ`(MS;0N-Q//3KGUH`YF?X=Z!>3&6]2YNY<8#SW#,0/SH`NZ
M5X1TW1)"=.>ZAC*E?*\]B@SZ*3@4`4I?AWX?NY%EO4N;R0#"M<7#L1].:`+F
MD^$=,T2X22P>ZA1,_N3.QCY']TG%`$^M^&M,\1V\4.IPF58GW(02K`^F1VH`
MKZ7X-TK1KB.;3OM%NJ?\LEN&\L\=U)P:`+^K:%IFN6X@U*SCN$'W=X^9?H:`
M,BW\%QV""'3=;U.S@48$2S!POTW`XH`;+X`TF]D675);S4I%Z&YG)4'U`&`*
M`+]SX5TVZT^WT\B>&S@78L,,Q16'OCDT`4['P'HFF3)-IR7-HP()\FX8!L=B
M,\T`=!=VBWEK);N\D8<8W1L59?H1TH`YF7X;>&IY6FN;66YF;[TDL[LQ_6@"
MU!X+L+6)8;>\U&*%>%1;ML*/09H`Z3%2[K8`P*8;"4"T#%`:!@>E-CM8:Y"@
MDG``R33]!Z&!H]W";F662=O,NI"(49B<*.E(1J:C<PQ6;++<FWWX0..HR<9H
M`E#K96:^=/D1J-TC]_K[T`+!=Q7*L8F)*D`C&"./>@"C<ZU!:ZBMLY&P(7>3
MJ$Y[T`:+31B`REAY>-VX>F.M`&%H5Y##;(;FY;SKJ0L@D))`[+GUH`WF<(A+
M,`H[F@"""_MYYWABD#N@!8`=*`&2ZM90O*CW*`Q+N<<\"@"5KVW2V%PTJK">
M0V.U`$0U:R,D:?:%S(NY?<4`26U]!>(SVT@=58J2!T-`"W%[;VB%II515&3G
ML*`)(I1-$DB$E&`(R,4`34`%`!0`4`%`"4`97B"9X=)D$9VER$+X)V@GDT`5
MK2Q226U$,96RM/F5F&&D>@!+[_2M>@M_)+)"!(Y"_>/89].]`#]8`.H:>;@D
M6:,SN0."P'&:`)-)BE\R\U&X1H_M#`HK\;448!/O0!D0N+NSU!H$#76H2%8T
MVXVITSGZ<T`:NIQ20:+#I]ODO+LMPV,X'0D_A0!##!;WDME;VBG[+:/O=R,9
M8<`?UH`=?WG_`!-)89(7DC@B\Q8PO$C>Y]A0!+H`8V<ES*I\VX8RNQ&`?8?2
M@"/2+-9KNYU"2+"NVR%2/NH/:@!^MJTRP:?`FV2?Y=^WB-!U^E`&8Z1Q&:\%
MNWV6P7R[="/OOW8T`:MBK:?HDDOENTN#(VX<R,><T`9#R-=+:6YCED%T!)/)
ML(+X_@'H*`.N7[O3'M0`Z@`H`*`"@`H`*`$-`!@>E`"4`(*`,GQ)</:Z)=/%
MPQ0@F@"[8QI'IUNJ*`!$H`_"@"U@>E`"#K0`&@!<4`*!0`'B@!*`%P/2@!H`
+(.1WH`?0`4`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
